medicines patent pool

March 2025

DISEASE BURDEN

In 2023, 39.9 million people globally were living with HIV, 1.3 million people became newly infected, and 630,000 people died of HIV, most of which occurred in LMICs.

CLINICAL RELEVANCE

GS-4182, an investigational lenacapavir prodrug with improved bioavailability, is being studied for once-weekly oral HIV treatment in combination with GS-1720 (an oral INSTI). Phase II/III WONDERS trials evaluating this regimen are ongoing.

INTELLECTUAL PROPERTY LANDSCAPE

In December 2022, Gilead filed three international patent applications covering lenacapavir pro-drugs, which may include GS-4182. Confirmation will be possible once the chemical structure of GS-4182 is available in the public domain. The expected expiry of the compound patents is 2042, and additional secondary patent filings are anticipated.

GS-4182

HIV TREATMENT

Gilead

SERVICE DELIVERY ENABLERS

An oral long-acting (weekly) HIV treatment regimen could be an important option that would combine advantages of long-acting therapies (e.g., adherence, discretion, no daily reminder of HIV) while minimising health system requirements (e.g., aligning with decentralised service delivery and multi-month dispensing efforts).

HIV: Human immunodeficiency virus; INSTI: Integrase strand transfer inhibitor; LMICs: low-income, lower middle-income and upper middle-income countries as per World Bank classification